


## Claims

1. A compound of the formula (I)




- 5 wherein

A is (C<sub>1</sub>-C<sub>4</sub>)-alkylene or CD<sub>2</sub>,

wherein (C<sub>1</sub>-C<sub>4</sub>)-alkylene is optionally substituted by hydroxyl and (C<sub>1</sub>-C<sub>4</sub>)-alkoxy and optionally up to pentasubstituted by fluorine,

or

- 10 A is a group of the formula



wherein

n is 0 or 1,

p is 0 or 1,

- 15 q is 1 or 2,

wherein

#<sup>1</sup> marks the bond to the nitrogen atom of the 5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl ring, and

\* marks the bond to R<sup>1</sup>,

- 20 X is -CR<sup>6</sup>R<sup>7</sup>-, #<sup>2</sup>-CR<sup>6</sup>R<sup>7</sup>-CR<sup>8</sup>R<sup>9</sup>-\*\*, #<sup>2</sup>-CR<sup>6</sup>=CR<sup>8</sup>-\*\*, or #<sup>2</sup>-CR<sup>6</sup>R<sup>7</sup>-CR<sup>8</sup>R<sup>9</sup>-CR<sup>10</sup>R<sup>11</sup>-\*\*,  
 \*\*,

wherein #<sup>2</sup> marks the bond to the carbon atom of the CR<sup>4</sup>R<sup>5</sup>- group, and

wherein \*\* marks the bond to the carbon atom of the 5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl ring;

wherein

R<sup>6</sup> is hydrogen, fluorine, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, trifluoromethoxy, hydroxyl, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino, or di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,

5 wherein (C<sub>1</sub>-C<sub>4</sub>)-alkyl is optionally substituted by (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, hydroxyl, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino or di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino and optionally up to pentasubstituted by fluorine,

R<sup>7</sup> is hydrogen, fluorine or (C<sub>1</sub>-C<sub>4</sub>)-alkyl,

wherein (C<sub>1</sub>-C<sub>4</sub>)-alkyl is optionally up to pentasubstituted by fluorine;

10 or

R<sup>6</sup> and R<sup>7</sup> together with the carbon atom to which they are bonded form a carbonyl group;

or

15 R<sup>6</sup> and R<sup>7</sup> together with the carbon atom to which they are bonded form a cyclopropyl ring, cyclobutyl ring or cyclopentyl ring;

or

R<sup>6</sup> and R<sup>4</sup> together with the carbon atom to which they are bonded form a cyclopropyl ring, cyclobutyl ring or cyclopentyl ring;

20 R<sup>8</sup> is hydrogen, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, fluorine, hydroxyl, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino, or di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,

wherein (C<sub>1</sub>-C<sub>4</sub>)-alkyl is optionally substituted by (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, hydroxyl, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino or di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino and optionally up to pentasubstituted by fluorine;

R<sup>9</sup> is hydrogen, fluorine or (C<sub>1</sub>-C<sub>4</sub>)-alkyl,

25 wherein (C<sub>1</sub>-C<sub>4</sub>)-alkyl is optionally up to pentasubstituted by fluorine;


or

R<sup>8</sup> and R<sup>9</sup> together with the carbon atom to which they are bonded form a cyclopropyl ring, cyclobutyl ring or cyclopentyl ring;

30 or







wherein

#<sup>3</sup> marks the bond to the carbonyl carbon atom,

r is 0 or 1,

5 Z is O, NR<sup>18</sup>, S, SO, SO<sub>2</sub> or CR<sup>14A</sup>R<sup>14B</sup>,

wherein

10 R<sup>14A</sup> is hydrogen, halogen, cyano, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl, trifluoromethyl, difluoromethyl, fluoromethyl, hydroxyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, (C<sub>3</sub>-C<sub>5</sub>)-cycloalkoxy, difluoromethoxy, trifluoromethoxy or 2,2,2-trifluoroethoxy,

wherein (C<sub>1</sub>-C<sub>4</sub>)-alkyl is optionally substituted by hydroxyl, amino, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino or di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,

15 R<sup>14B</sup> is hydrogen, fluorine or (C<sub>1</sub>-C<sub>4</sub>)-alkyl,

wherein (C<sub>1</sub>-C<sub>4</sub>)-alkyl is optionally up to pentasubstituted by fluorine,

or

R<sup>14A</sup> and R<sup>14B</sup> together with the carbon atom to which they are bonded form a carbonyl group,

20 R<sup>18</sup> is hydrogen or methyl,

R<sup>12</sup> is hydrogen, cyano, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, acetyl or formyl,

wherein (C<sub>1</sub>-C<sub>4</sub>)-alkyl is optionally substituted by hydroxyl or up to pentasubstituted by fluorine,

25 wherein acetyl is optionally substituted by hydroxyl or up to trisubstituted by fluorine,

R<sup>13</sup> is hydrogen, fluorine or (C<sub>1</sub>-C<sub>4</sub>)-alkyl,

or

R<sup>12</sup> and R<sup>13</sup> together with the carbon atoms to which they are bonded form a cyclopropyl or cyclobutyl ring,

wherein the cyclopropyl or cyclobutyl ring is optionally up to disubstituted by fluorine,

5 or

R<sup>13</sup> and R<sup>14A</sup> together with the carbon atoms to which they are bonded form a cyclopropyl or cyclobutyl ring,

wherein the cyclopropyl or cyclobutyl ring is optionally up to disubstituted by fluorine,

10 or

R<sup>14A</sup> and R<sup>14B</sup> together with the carbon atom to which they are bonded form a cyclopropyl or cyclobutyl ring,


wherein the cyclopropyl or cyclobutyl ring is optionally up to disubstituted by fluorine,

15 wherein R<sup>13</sup>, R<sup>14A</sup> and R<sup>14B</sup> are hydrogen when R<sup>12</sup> is not hydrogen,

wherein R<sup>12</sup> is hydrogen when one of the R<sup>13</sup>, R<sup>14A</sup> and R<sup>14B</sup> substituents is not hydrogen;

or

R<sup>2</sup> is a group of the formula



wherein

#<sup>4</sup> marks the bond to the carbonyl carbon atom,

Y is NR<sup>15</sup>, CR<sup>16A</sup>R<sup>16B</sup>, oxygen or sulphur,

wherein

25 R<sup>15</sup> is hydrogen or methyl,

R<sup>16A</sup> is hydrogen or methyl,

R<sup>16B</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen or (C<sub>1</sub>-C<sub>4</sub>)-alkyl;

R<sup>4</sup> is hydrogen, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, fluorine, hydroxyl, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino, or di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,

wherein (C<sub>1</sub>-C<sub>4</sub>)-alkyl is optionally substituted by (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, hydroxyl, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino or di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino and optionally up to pentasubstituted by fluorine;

R<sup>5</sup> is hydrogen or (C<sub>1</sub>-C<sub>4</sub>)-alkyl,

wherein (C<sub>1</sub>-C<sub>4</sub>)-alkyl is optionally up to pentasubstituted by fluorine;

or

R<sup>4</sup> and R<sup>5</sup> together with the carbon atom to which they are bonded form a carbonyl group;

or

R<sup>4</sup> and R<sup>5</sup> together with the carbon atom to which they are bonded form a cyclopropyl ring, cyclobutyl ring or cyclopentyl ring,

or a salt, a solvate, or a solvate of a salt thereof.


2. The compound according to Claim 1, wherein

A is (C<sub>1</sub>-C<sub>4</sub>)-alkylene,

wherein (C<sub>1</sub>-C<sub>4</sub>)-alkylene is optionally substituted by hydroxyl and methoxy and is optionally up to trisubstituted by fluorine;

or

A is a group of the formula



wherein

n is 1,

p is 0,

q is 1,

wherein

#<sup>1</sup> marks the bond to the nitrogen atom of the 5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl ring,

\* marks the bond to R<sup>1</sup>;

X is -CR<sup>6</sup>R<sup>7</sup>- or #<sup>2</sup>-CR<sup>6</sup>R<sup>7</sup>-CR<sup>8</sup>R<sup>9</sup>-\*\*,

wherein #<sup>2</sup> marks the bond to the carbon atom of the CR<sup>4</sup>R<sup>5</sup>- group,

wherein \*\* marks the bond to the carbon atom of the 5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl ring;

wherein

R<sup>6</sup> is hydrogen, fluorine, methyl, ethyl, methoxy, ethoxy, trifluoromethoxy, hydroxyl, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino or di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,

wherein methyl and ethyl is optionally up to trisubstituted by fluorine;

R<sup>7</sup> is hydrogen, fluorine or methyl,

wherein methyl is optionally up to trisubstituted by fluorine;

or

R<sup>6</sup> and R<sup>7</sup> together with the carbon atom to which they are bonded form a carbonyl group;

or

R<sup>6</sup> and R<sup>7</sup> together with the carbon atom to which they are bonded form a cyclopropyl or cyclobutyl ring;

or

R<sup>6</sup> and R<sup>4</sup> together with the carbon atoms to which they are bonded form a cyclopropyl or cyclobutyl ring;

R<sup>8</sup> is hydrogen, fluorine, methyl, ethyl, methoxy, ethoxy, hydroxyl, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino or di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,

wherein methyl and ethyl are optionally up to trisubstituted by fluorine;

R<sup>9</sup> is hydrogen, fluorine or methyl,

wherein methyl is optionally up to trisubstituted by fluorine;

or

R<sup>8</sup> and R<sup>9</sup> together with the carbon atom to which they are bonded form a cyclopropyl or cyclobutyl ring;

R<sup>1</sup> is (C<sub>5</sub>-C<sub>6</sub>)-cycloalkyl, phenyl or 5- to 6-membered heteroaryl,  
wherein (C<sub>5</sub>-C<sub>6</sub>)-cycloalkyl is optionally substituted by 1 to 3 substituents  
independently selected from the group consisting of fluorine, cyano,  
trifluoromethyl, methyl, ethyl, methoxy and ethoxy,

5                                wherein methyl and ethyl are optionally up to trisubstituted by fluorine,  
wherein phenyl is substituted by 1 to 4 substituents independently selected  
from the group consisting of halogen, cyano, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl,  
trifluoromethyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, (C<sub>3</sub>-C<sub>5</sub>)-cycloalkoxy, monofluoromethoxy,  
difluoromethoxy, trifluoromethoxy, hydroxycarbonyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl,  
10                                aminocarbonyl, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylaminocarbonyl, di-(C<sub>1</sub>-C<sub>4</sub>)-  
alkylaminocarbonyl, (C<sub>1</sub>-C<sub>4</sub>)-alkylsulphanyl, (C<sub>1</sub>-C<sub>4</sub>)-alkylsulphonyl, (C<sub>1</sub>-C<sub>4</sub>)-  
alkylsulphonimidoyl, aminosulphonyl, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylaminosulphonyl, di-  
(C<sub>1</sub>-C<sub>4</sub>)-alkylaminosulphonyl, (C<sub>1</sub>-C<sub>4</sub>)-alkylsulphinyl, amino, mono-(C<sub>1</sub>-C<sub>4</sub>)-  
alkylamino, and di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,

15                                or

wherein phenyl is optionally fused to cyclopentyl, cyclohexyl, 5- to 6-  
membered heterocyclyl or 5- to 6-membered heteroaryl,

wherein phenyl is optionally substituted by methyl, ethyl, chlorine,  
fluorine or methoxy,

20                                wherein cyclopentyl, cyclohexyl, 5- to 6-membered heterocyclyl and 5-  
to 6-membered heteroaryl are optionally substituted by 1 or 2 methyl or  
ethyl substituents,

wherein methyl and ethyl are optionally substituted by methoxy,  
hydroxyl, monomethylamino or diethylamino and optionally up  
25                                to trisubstituted by fluorine,

or

wherein 5- to 10-membered heteroaryl is optionally substituted by 1 to 4  
substituents independently selected from the group consisting of halogen,  
cyano, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl, trifluoromethyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, (C<sub>3</sub>-C<sub>5</sub>)-  
30                                cycloalkoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy,  
hydroxycarbonyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl, aminocarbonyl, mono-(C<sub>1</sub>-C<sub>4</sub>)-  
alkylaminocarbonyl, di-(C<sub>1</sub>-C<sub>4</sub>)-alkylaminocarbonyl, (C<sub>1</sub>-C<sub>4</sub>)-alkylsulphanyl, (C<sub>1</sub>-  
C<sub>4</sub>)-alkylsulphonyl, (C<sub>1</sub>-C<sub>4</sub>)-alkylsulphonimidoyl, aminosulphonyl, mono-(C<sub>1</sub>-

C<sub>4</sub>)-alkylaminosulphonyl, di-(C<sub>1</sub>-C<sub>4</sub>)-alkylaminosulphonyl, (C<sub>1</sub>-C<sub>4</sub>)-alkylsulphanyl, amino, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino, and di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino, or


wherein said 5- to 6-membered heteroaryl of R<sup>1</sup> is optionally fused to cyclopentyl, cyclohexyl, phenyl or 5- to 6-membered heterocyclyl,

wherein said 5- to 10-membered heteroaryl of R<sup>1</sup> is optionally substituted by methyl, ethyl, chlorine, fluorine or methoxy,

wherein cyclopentyl, cyclohexyl, phenyl and 5- to 6-membered heterocyclyl fused to said 5- to 6-membered heteroaryl of R<sup>1</sup> are optionally substituted by 1 or 2 (C<sub>1</sub>-C<sub>4</sub>)-alkyl substituents,

wherein (C<sub>1</sub>-C<sub>4</sub>)-alkyl is optionally substituted by (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, hydroxyl, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino or di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino and up to pentasubstituted by fluorine;

R<sup>2</sup> is a group of the formula



wherein

#<sup>3</sup> marks the bond to the carbonyl carbon atom,

r is 0 or 1,

Z is S, SO, SO<sub>2</sub> or CR<sup>14A</sup>R<sup>14B</sup>,

wherein

R<sup>14A</sup> is hydrogen, halogen, cyano, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, cyclopropyl, trifluoromethyl, difluoromethyl, fluoromethyl, hydroxyl, methoxy, ethoxy, cyclopropoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, hydroxycarbonyl, aminocarbonyl or amino,

wherein (C<sub>1</sub>-C<sub>4</sub>)-alkyl is optionally substituted by hydroxyl, amino, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino or di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,

R<sup>14B</sup> is hydrogen, fluorine, methyl or trifluoromethyl,

or

R<sup>14A</sup> and R<sup>14B</sup> together with the carbon atom to which they are bonded form a carbonyl group,

R<sup>12</sup> is hydrogen, cyano, methyl, ethyl, acetyl or formyl,

wherein methyl is optionally substituted by hydroxyl or up to pentasubstituted by fluorine,

wherein acetyl is substituted by hydroxyl or up to trisubstituted by fluorine,

R<sup>13</sup> is hydrogen, fluorine or methyl,

or

R<sup>12</sup> and R<sup>13</sup> together with the carbon atoms to which they are bonded form a cyclopropyl ring,

wherein the cyclopropyl ring is optionally up to disubstituted by fluorine,

or

R<sup>13</sup> and R<sup>14A</sup> together with the carbon atoms to which they are bonded form a cyclopropyl or cyclobutyl ring,

wherein the cyclopropyl or cyclobutyl ring is optionally up to disubstituted by fluorine,

or

R<sup>14A</sup> and R<sup>14B</sup> together with the carbon atom to which they are bonded form a cyclopropyl or cyclobutyl ring,


wherein the cyclopropyl or cyclobutyl ring is optionally up to disubstituted by fluorine,

R<sup>13</sup>, R<sup>14A</sup> and R<sup>14B</sup> are hydrogen when R<sup>12</sup> is not hydrogen,

wherein R<sup>12</sup> is hydrogen when one of the R<sup>13</sup>, R<sup>14A</sup> and R<sup>14B</sup> substituents is not hydrogen;

or

R<sup>2</sup> is a group of the formula



wherein

#<sup>4</sup> marks the bond to the carbonyl carbon atom,

Y is NR<sup>15</sup>, CR<sup>16A</sup>R<sup>16B</sup>, oxygen or sulphur,

wherein

R<sup>15</sup> is hydrogen or methyl,

5 R<sup>16A</sup> is hydrogen or methyl,

R<sup>16B</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen or methyl;

R<sup>4</sup> is hydrogen, fluorine, methyl, ethyl, methoxy, ethoxy, trifluoromethoxy, hydroxyl, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino, or di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,

10 wherein methyl and ethyl are optionally up to trisubstituted by fluorine;

R<sup>5</sup> is hydrogen, or methyl,

wherein methyl is optionally up to trisubstituted by fluorine;

or

15 R<sup>4</sup> and R<sup>5</sup> together with the carbon atom to which they are bonded form a cyclopropyl ring,

or a salt, a solvate, or a solvate of a salt thereof.

3. The compound according to Claim 1 or 2, wherein

A is -CH<sub>2</sub>-, -CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>-, #<sup>5</sup>-CH<sub>2</sub>CH(CH<sub>3</sub>)-<sup>\*\*\*</sup>, #<sup>5</sup>-CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-<sup>\*\*\*</sup>, #<sup>5</sup>-CH<sub>2</sub>CHF-<sup>\*\*\*</sup> or #<sup>5</sup>-CH<sub>2</sub>CF<sub>2</sub>-<sup>\*\*\*</sup>,

20 wherein #<sup>5</sup> marks the bond to the nitrogen atom of the 5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl ring,

wherein <sup>\*\*\*</sup> marks the bond to the R<sup>1</sup> group;

X is - #<sup>2</sup>-CR<sup>6</sup>R<sup>7</sup>-CR<sup>8</sup>R<sup>9</sup>-<sup>\*\*</sup>,

wherein #<sup>2</sup> marks the bond to the carbon atom of the CR<sup>4</sup>R<sup>5</sup>- group,

25 wherein <sup>\*\*</sup> marks the bond to the carbon atom of the 5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl ring,

wherein

R<sup>6</sup> is hydrogen, fluorine, methyl, trifluoromethyl or hydroxyl;

R<sup>7</sup> is hydrogen, fluorine or methyl;

or

R<sup>6</sup> and R<sup>7</sup> together with the carbon atom to which they are bonded form a cyclopropyl ring;

R<sup>8</sup> is hydrogen, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, fluorine, hydroxyl, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino, or di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,

wherein (C<sub>1</sub>-C<sub>4</sub>)-alkyl is optionally substituted by (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, hydroxyl, mono-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino or di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino and optionally up to pentasubstituted by fluorine;

R<sup>9</sup> is hydrogen, fluorine or (C<sub>1</sub>-C<sub>4</sub>)-alkyl,

wherein (C<sub>1</sub>-C<sub>4</sub>)-alkyl is optionally up to pentasubstituted by fluorine;

or

R<sup>8</sup> and R<sup>9</sup> together with the carbon atom to which they are bonded form a cyclopropyl ring, cyclobutyl ring, or cyclopentyl ring;

or

R<sup>7</sup> and R<sup>9</sup> together with the carbon atoms to which they are bonded form a cyclopropyl ring, cyclobutyl ring, or cyclopentyl ring;

R<sup>1</sup> is phenyl or 5- to 6-membered heteroaryl,

wherein phenyl is substituted by 1 to 3 substituents independently selected from the group consisting of fluorine, chlorine, cyano, methyl, ethyl, trifluoromethyl, methoxy, difluoromethoxy, trifluoromethoxy, hydroxycarbonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulphanyl, methylsulphonyl, methylsulphonimidoyl, aminosulphonyl, and methylsulphinyl;

or

wherein phenyl is optionally fused to cyclopentyl, cyclohexyl, 5- to 6-membered heterocyclyl or 5- to 6-membered heteroaryl,

wherein cyclopentyl, cyclohexyl, 5- to 6-membered heterocyclyl and 5- to 6-membered heteroaryl are optionally substituted by 1 or 2 methyl or ethyl substituents;

or

wherein 5- to 6-membered heteroaryl is optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluorine, chlorine, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, methylaminocarbonyl, tert-butylaminocarbonyl, and dimethylaminocarbonyl;


or

wherein said 5- to 6-membered heteroaryl of  $R^1$  is optionally fused to cyclopentyl, cyclohexyl, 5- to 6-membered heterocyclyl, phenyl or 5- to 6-membered heteroaryl,

wherein said 5- to 6-membered heteroaryl of  $R^1$  is optionally substituted by methyl, ethyl, chlorine, fluorine or methoxy, and

wherein the cyclopentyl, cyclohexyl, 5- to 6-membered heterocyclyl, phenyl and 5- to 6-membered heteroaryl fused to said 5- to 6-membered heteroaryl of  $R^1$  are optionally substituted by 1 or 2 ( $C_1$ - $C_4$ )-alkyl substituents;

$R^2$  is a group of the formula



wherein

$\#^3$  marks the bond to the carbonyl carbon atom,

$r$  is 0 or 1,

$Z$  is S or  $CR^{14A}R^{14B}$  when  $r$  is 0,

$Z$  is S, SO,  $SO_2$  or  $CR^{14A}R^{14B}$  when  $r$  is 1,

in each of which

$R^{14A}$  is hydrogen, fluorine, methyl, trifluoromethyl, difluoromethyl, fluoromethyl, hydroxyl, methoxy, difluoromethoxy, or trifluoromethoxy,

$R^{14B}$  is hydrogen or fluorine,

or

R<sup>14A</sup> and R<sup>14B</sup> together with the carbon atom to which they are bonded form a carbonyl group,

R<sup>12</sup> is hydrogen, cyano, methyl, acetyl or formyl,

wherein acetyl is substituted by hydroxyl or up to trisubstituted by fluorine,

R<sup>13</sup> is hydrogen, fluorine or methyl,

or

R<sup>12</sup> and R<sup>13</sup> together with the carbon atoms to which they are bonded form a cyclopropyl ring,

or

R<sup>13</sup> and R<sup>14A</sup> together with the carbon atom to which they are bonded form a cyclopropyl ring,

wherein the cyclopropyl ring is optionally up to disubstituted by fluorine,

or

R<sup>14A</sup> and R<sup>14B</sup> together with the carbon atom to which they are bonded form a cyclopropyl ring,

wherein the cyclopropyl ring is optionally up to disubstituted by fluorine,

wherein R<sup>13</sup>, R<sup>14A</sup> and R<sup>14B</sup> are hydrogen when R<sup>12</sup> is not hydrogen,

wherein R<sup>12</sup> is hydrogen when one of the R<sup>13</sup>, R<sup>14A</sup> and R<sup>14B</sup> substituents is not hydrogen;

R<sup>3</sup> is hydrogen;

R<sup>4</sup> is hydrogen, fluorine or methyl; and

R<sup>5</sup> is hydrogen,

or a salt, a solvate, or a solvate of a salt thereof.

4. The compound according to Claim 1, 2 or 3, wherein:

A is -CH<sub>2</sub>-, -CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>-, #<sup>5</sup>-CH<sub>2</sub>CH(CH<sub>3</sub>)-<sup>\*\*\*</sup>, #<sup>5</sup>-CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-<sup>\*\*\*</sup>, #<sup>5</sup>-CH<sub>2</sub>CHF-<sup>\*\*\*</sup> or #<sup>5</sup>-CH<sub>2</sub>CF<sub>2</sub>-<sup>\*\*\*</sup>,

wherein #<sup>5</sup> marks the bond to the nitrogen atom of the 5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl ring,

wherein <sup>\*\*\*</sup> marks the bond to the R<sup>1</sup> group;

X is - #<sup>2</sup>-CR<sup>6</sup>R<sup>7</sup>-CR<sup>8</sup>R<sup>9</sup>-\*\*,  
 wherein #<sup>2</sup> marks the bond to the carbon atom of the CR<sup>4</sup>R<sup>5</sup>- group,  
 wherein \*\* marks the bond to the carbon atom of the 5-oxo-4,5-dihydro-1H-  
 1,2,4-triazol-1-yl ring;

5 wherein

R<sup>6</sup> is hydrogen, fluorine, methyl, trifluoromethyl, or hydroxyl;  
 R<sup>7</sup> is hydrogen, fluorine, or methyl;  
 or

10 R<sup>6</sup> and R<sup>7</sup> together with the carbon atom to which they are bonded form a cyclopropyl ring;

R<sup>8</sup> is hydrogen, fluorine, methyl, or trifluoromethyl;  
 R<sup>9</sup> is hydrogen, fluorine, or methyl;

R<sup>1</sup> is phenyl or 5- to 6-membered heteroaryl,  
 wherein phenyl is substituted by 1 to 3 substituents independently selected  
 15 from the group consisting of fluorine, chlorine, cyano, methyl, ethyl, trifluoromethyl, methoxy, difluoromethoxy, trifluoromethoxy, hydroxycarbonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulphanyl, methylsulphonyl, methylsulphonimidoyl, aminosulphonyl, and methylsulphinyl;

20 or

wherein phenyl is optionally fused to cyclopentyl, cyclohexyl, 5- to 6-membered heterocyclyl or 5- to 6-membered heteroaryl,  
 wherein cyclopentyl, cyclohexyl, 5- to 6-membered heterocyclyl and 5-  
 25 to 6-membered heteroaryl are optionally substituted by 1 or 2 methyl or ethyl substituents;

or

wherein 5- to 6-membered heteroaryl is optionally substituted by 1 to 3  
 30 substituents independently selected from the group consisting of fluorine, chlorine, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, methylaminocarbonyl, tert-butylaminocarbonyl, and dimethylaminocarbonyl;

or


wherein said 5- to 6-membered heteroaryl of  $R^1$  is optionally fused to cyclopentyl, cyclohexyl, 5- to 6-membered heterocyclyl, phenyl or 5- to 6-membered heteroaryl,

5                    wherein said 5- to 6-membered heteroaryl of  $R^1$  is optionally substituted by methyl, ethyl, chlorine, fluorine or methoxy,

                    wherein the cyclopentyl, cyclohexyl, 5- to 6-membered heterocyclyl, phenyl and 5- to 6-membered heteroaryl fused to said 5- to 6-membered heteroaryl of  $R^1$  are optionally substituted by 1 or 2 ( $C_1$ - $C_4$ )-alkyl substituents;

10

$R^2$         is a group of the formula



wherein

$\#^3$  marks the bond to the carbonyl carbon atom,

15            r        is 0 or 1,

Z        is S or  $CR^{14A}R^{14B}$  when r is 0, or

Z        is S, SO,  $SO_2$  or  $CR^{14A}R^{14B}$  when r is 1,

in each of which

20             $R^{14A}$     is hydrogen, fluorine, methyl, trifluoromethyl, difluoromethyl, fluoromethyl, hydroxyl, methoxy, difluoromethoxy or trifluoromethoxy,

$R^{14B}$     is hydrogen or fluorine,

or

25             $R^{14A}$  and  $R^{14B}$  together with the carbon atom to which they are bonded form a carbonyl group,

$R^{12}$         is hydrogen, cyano, methyl, acetyl or formyl,

wherein acetyl is substituted by hydroxyl or up to trisubstituted by fluorine,

R<sup>13</sup> is hydrogen, fluorine or methyl,

or

R<sup>12</sup> and R<sup>13</sup> together with the carbon atoms to which they are bonded form a cyclopropyl ring,

5 or

R<sup>13</sup> and R<sup>14A</sup> together with the carbon atom to which they are bonded form a cyclopropyl ring,

wherein the cyclopropyl ring is optionally up to disubstituted by fluorine,

or

10 R<sup>14A</sup> and R<sup>14B</sup> together with the carbon atom to which they are bonded form a cyclopropyl ring,

wherein the cyclopropyl ring is optionally up to disubstituted by fluorine,

wherein R<sup>13</sup>, R<sup>14A</sup> and R<sup>14B</sup> are hydrogen when R<sup>12</sup> is not hydrogen,

wherein R<sup>12</sup> is hydrogen when one of the R<sup>13</sup>, R<sup>14A</sup> and R<sup>14B</sup> substituents is not hydrogen;

15

R<sup>3</sup> is hydrogen,

R<sup>4</sup> is hydrogen, fluorine, or methyl; and

R<sup>5</sup> is hydrogen,

or a salt, a solvate, or a solvate of a salt thereof.

20 5. The compound according to Claim 1, 2 or 3, wherein:

A is -CH<sub>2</sub>-, -CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>-, #<sup>5</sup>-CH<sub>2</sub>CH(CH<sub>3</sub>)-<sup>\*\*\*</sup>, #<sup>5</sup>-CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-<sup>\*\*\*</sup>, #<sup>5</sup>-CH<sub>2</sub>CHF-<sup>\*\*\*</sup> or #<sup>5</sup>-CH<sub>2</sub>CF<sub>2</sub>-<sup>\*\*\*</sup>,

wherein #<sup>5</sup> marks the bond to the nitrogen atom of the 5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl ring,

25 wherein <sup>\*\*\*</sup> marks the bond to the R<sup>1</sup> group;

X is - #<sup>2</sup>-CR<sup>6</sup>R<sup>7</sup>-CR<sup>8</sup>R<sup>9</sup>-<sup>\*\*</sup>,

wherein #<sup>2</sup> marks the bond to the carbon atom of the CR<sup>4</sup>R<sup>5</sup>- group,

wherein <sup>\*\*</sup> marks the bond to the carbon atom of the 5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl ring;

30 wherein

R<sup>6</sup> is hydrogen, fluorine, methyl, trifluoromethyl, or hydroxyl;

R<sup>7</sup> is hydrogen, fluorine, or methyl;

or

5 R<sup>6</sup> and R<sup>7</sup> together with the carbon atom to which they are bonded form a cyclopropyl ring;

R<sup>8</sup> is hydrogen, fluorine, methyl or trifluoromethyl;

R<sup>9</sup> is hydrogen, fluorine or methyl;

R<sup>1</sup> is phenyl, pyrazolyl, imidazolyl, thiazolyl, thiophenyl, oxazolyl, oxadiazolyl, or pyridyl,

10 wherein phenyl is substituted by 1 to 3 substituents independently selected from the group consisting of fluorine, chlorine, cyano, methyl, ethyl, trifluoromethyl, methoxy, difluoromethoxy, trifluoromethoxy, hydroxycarbonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulphanyl, methylsulphonyl,  
15 methylsulphonimidoyl, aminosulphonyl, and methylsulphinyl;

or

wherein phenyl is optionally fused to cyclopentyl, cyclohexyl, pyrazolyl, or pyridyl,

20 wherein cyclopentyl, cyclohexyl, pyrazolyl or pyridyl is optionally substituted by 1 or 2 methyl or ethyl substituents;

or

25 wherein said pyrazolyl, imidazolyl, thiazolyl, thiophenyl, oxazolyl, oxadiazolyl or pyridyl of R<sup>1</sup> is optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluorine, chlorine, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, methylaminocarbonyl, tert-butylaminocarbonyl, and dimethylaminocarbonyl;


or

30 wherein said pyrazolyl, imidazolyl, thiazolyl, thiophenyl, oxazolyl, oxadiazolyl or pyridyl of R<sup>1</sup> is optionally fused to cyclopentyl, cyclohexyl, phenyl or pyridyl,

wherein said pyridyl of R<sup>1</sup> is optionally substituted by methyl, ethyl, chlorine, fluorine, or methoxy,

wherein the cyclopentyl, cyclohexyl, phenyl and pyridyl fused to said pyrazolyl, imidazolyl, thiazolyl, thiophenyl, oxazolyl, oxadiazolyl or pyridyl of R<sup>1</sup> are optionally substituted by 1 or 2 (C<sub>1</sub>-C<sub>4</sub>)-alkyl substituents;

5            R<sup>2</sup>        is a group of the formula



wherein

#<sup>3</sup> marks the bond to the carbonyl carbon atom,

r        is 0 or 1,

10        Z        is S or CR<sup>14A</sup>R<sup>14B</sup> when r is 0,

Z        is S, SO, SO<sub>2</sub> or CR<sup>14A</sup>R<sup>14B</sup> when r is 1,

in each of which

15        R<sup>14A</sup>    is hydrogen, fluorine, methyl, trifluoromethyl, difluoromethyl, fluoromethyl, hydroxyl, methoxy, difluoromethoxy or trifluoromethoxy,

R<sup>14B</sup>    is hydrogen or fluorine,

or

R<sup>14A</sup> and R<sup>14B</sup> together with the carbon atom to which they are bonded form a carbonyl group,

20        R<sup>12</sup>    is hydrogen, cyano, methyl, acetyl or formyl,

wherein acetyl is substituted by hydroxyl or up to trisubstituted by fluorine,

R<sup>13</sup>    is hydrogen, fluorine, or methyl,

or

25        R<sup>12</sup> and R<sup>13</sup> together with the carbon atoms to which they are bonded form a cyclopropyl ring,

or

R<sup>13</sup> and R<sup>14A</sup> together with the carbon atom to which they are bonded form a cyclopropyl ring,

wherein the cyclopropyl ring is optionally up to disubstituted by fluorine,

or

5 R<sup>14A</sup> and R<sup>14B</sup> together with the carbon atom to which they are bonded form a cyclopropyl ring,

wherein the cyclopropyl ring is optionally up to disubstituted by fluorine,

wherein R<sup>13</sup>, R<sup>14A</sup> and R<sup>14B</sup> are hydrogen when R<sup>12</sup> is not hydrogen,

10 wherein R<sup>12</sup> is hydrogen when one of the R<sup>13</sup>, R<sup>14A</sup> and R<sup>14B</sup> substituents is not hydrogen;


R<sup>3</sup> is hydrogen;

R<sup>4</sup> is hydrogen, fluorine, or methyl; and


R<sup>5</sup> is hydrogen,

or a salt, a solvate, or a solvate of a salt thereof.


15 6. The compound according to claim 1, wherein the compound is (5RS,7RS)-2-[(6-chloropyridin-3-yl)methyl]-5-[[[(3R,4S)-3,4-difluoropyrrolidin-1-yl]carbonyl]-7-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (enantiomer 1) of the formula



20 7. The compound according to claim 1, wherein the compound is (5S,7R)-5-[[[(3S)-3-fluoropyrrolidin-1-yl]carbonyl]-7-(trifluoromethyl)-2-[[6-(trifluoromethyl)pyridine-3-yl]methyl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (isomer 1) of the formula




8. The compound according to claim 1, wherein the compound is (5S)-5-[[[(3R,4S)-3,4-difluoropyrrolidin-1-yl]carbonyl]-2-[[3-fluoro-2-(trifluoromethyl)pyridin-4-yl]methyl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one of the formula




5

9. The compound according to claim 1, wherein the compound is (5S)-5-[[[(3S)-3-fluoropyrrolidin-1-yl]carbonyl]-2-[[6-(trifluoromethyl)pyridin-3-yl]methyl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one of the formula



10. A process for preparing a compound of formula (I) according to Claim 1,



wherein

5 A is  $-\text{CH}_2-$ ,  $-\text{CH}(\text{CH}_3)-$ ,  $-\text{CH}_2\text{CH}_2-$ ,  $\#^5\text{-CH}_2\text{CH}(\text{CH}_3)\text{-}^{***}$ ,  $\#^5\text{-CH}_2\text{C}(\text{CH}_2)_2\text{-}^{***}$ ,  $\#^5\text{-CH}_2\text{CHF-}^{***}$ , or  $\#^5\text{-CH}_2\text{CF}_2\text{-}^{***}$ ,


wherein  $\#^5$  marks the bond to the nitrogen atom of the 5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl ring,

wherein  $^{***}$  marks the bond to the  $\text{R}^1$  group, and

10 wherein  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$  and X are as defined in claim 1,

comprising either

[A] reacting a compound of the formula (II)




wherein  $R^3$ ,  $R^4$ ,  $R^5$  and  $X$  are as defined in claim 1,

and

$T^1$  is  $(C_1-C_4)$ -alkyl or benzyl,

in an inert solvent in the presence of a suitable base with a compound of the formula (III)



wherein

$A^1$  is  $-\text{CH}_2-$ ,  $-\text{CH}(\text{CH}_3)-$ ,  $-\text{CH}_2\text{CH}_2-$ ,  $\#^5-\text{CH}_2\text{CH}(\text{CH}_3)-^{***}$ ,  $\#^5-\text{CH}_2\text{C}(\text{CH}_3)_2-^{***}$ ,  $\#^5-\text{CH}_2\text{CHF}-^{***}$  or  $\#^5-\text{CH}_2\text{CF}_2-^{***}$ ,

wherein  $\#^5$  marks the bond to the nitrogen atom of the 5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl ring,


wherein  $^{***}$  marks the bond to the  $R^1$  group,

$R^1$  is as defined in claim 1,

and


$X^1$  is a suitable leaving group,

to give a compound of the formula (IV)



wherein  $A^1$ ,  $R^1$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $X$  and  $T^1$  are as defined above;


converting the compound of formula (IV) to a compound of formula (V) by removing the " $T^1$ " group in an inert solvent in the presence of a suitable base or acid



(V),


wherein A<sup>1</sup>, R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and X are as defined above;

reacting the compound of formula (V) in an inert solvent under amide coupling conditions with an amine of the formula (VI-A) or (VI-B)



(VI-A)

or




(VI-B)

wherein Y, Z, r, R<sup>12</sup> and R<sup>13</sup> are as defined in claim 1;

thereby providing the compound of the formula (I); and optionally converting the compound of formula (I) with the appropriate (i) solvents and/or (ii) acids or bases to the solvate, the salt or the solvate of the salt thereof;

or

[B] reacting a compound of the formula (II)



(II)


wherein R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and X are as defined in claim 1,

and

T<sup>1</sup> is (C<sub>1</sub>-C<sub>4</sub>)-alkyl or benzyl,


in an inert solvent in the presence of a suitable base with

an amine of the formula (VI-A) or (VI-B)




wherein Y, Z, r, R<sup>12</sup> and R<sup>13</sup> are as defined in claim 1,

to give a compound of the formula (XXIII-A) or (XXIII-B)



5      wherein R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>12</sup>, R<sup>13</sup>, X, Y, Z, and r are as defined above;

reacting the compound of formula (XXIII-A) or the compound of formula (XXIII-B) in an inert solvent in the presence of a suitable base with a compound of the formula (III)



10      wherein

A<sup>1</sup>      is -CH<sub>2</sub>-, -CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>-, #<sup>5</sup>-CH<sub>2</sub>CH(CH<sub>3</sub>)-<sup>\*\*\*</sup>, #<sup>5</sup>-CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-<sup>\*\*\*</sup>, #<sup>5</sup>-CH<sub>2</sub>CHF-<sup>\*\*\*</sup> or #<sup>5</sup>-CH<sub>2</sub>CF<sub>2</sub>-<sup>\*\*\*</sup>,

wherein #<sup>5</sup> marks the bond to the nitrogen atom of the 5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl ring,

15      wherein <sup>\*\*\*</sup> marks the bond to the R<sup>1</sup> group,

R<sup>1</sup>      is as defined in claim 1,

and

X<sup>1</sup>      is a suitable leaving group;

thereby providing the compound of the formula (I); and optionally further converting the compound of formula (I) with the appropriate (i) solvents and/or (ii) acids or bases to the solvate, the salt, or the solvate of the salt thereof;

20

[C] converting a compound of the formula (VII)



5 T<sup>1</sup> is (C<sub>1</sub>-C<sub>4</sub>)-alkyl or benzyl,

by hydrolysis of the ester group in an inert solvent in the presence of a suitable base or acid to a compound of the formula (VIII)




10

wherein Y, Z, r,  $R^{12}$  and  $R^{13}$  are as defined in claim 1,


15



or




(VI-B)




wherein  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^{12}$ ,  $R^{13}$ ,  $T^2$ ,  $X$ ,  $Y$ ,  $Z$ , and  $r$  are as defined above;

removing the protecting group " $T^2$ " in an inert solvent in the presence of a suitable base or acid or optionally in the presence of a suitable palladium catalyst to provide a compound of formula (X-A) or (X-B)



wherein  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^{12}$ ,  $R^{13}$ ,  $X$ ,  $Y$ ,  $Z$ , and  $r$  are as defined above;

reacting the compound of formula (X-A) or (X-B) in an inert solvent in the presence of a suitable base with a compound of the formula (III)



wherein

$A^1$   $AR^1$  is as defined in claim 1,

and

$X^1$  is a suitable leaving group; thereby providing the compound of the formula (I); and optionally further converting the compound of formula (I) with the appropriate (i) solvents and/or (ii) acids or bases to the solvate, the salt, or the solvate of the salt thereof.

11. The process according to claim 10, wherein  $X^1$  is chlorine, bromine, iodine, mesylate {(methylsulphonyl)oxy}, triflate {[trifluoromethylsulphonyl]oxy}, nonaflate

{[(nonafluorobutyl)sulphonyl]oxy}, nosylate {[[(4-nitrophenyl)sulphonyl]oxy} or tosylate {[[(4-methylphenyl) sulphonyl] oxy}.

12. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 9 in combination with one or more inert, nontoxic, pharmaceutically suitable excipients.

13. A pharmaceutical combination comprising a compound according to any one of Claims 1 to 9 in combination with one or more active ingredients selected from the group consisting of the PDE 5 inhibitors, sGC activators, sGC stimulators, prostacyclin analogues, IP receptor agonists, endothelin antagonists, compounds that inhibit the signal transduction cascade, and pirfenidone.

14. A compound of the formula (I) as defined in any one of Claims 1 to 9, a pharmaceutical composition according to Claim 12, or a pharmaceutical combination according to Claim 13, for use in the treatment and/or prophylaxis of diseases.

15. Use of a compound of the formula (I) as defined in any one of Claims 1 to 9, a pharmaceutical composition according to Claim 12, or a pharmaceutical combination according to Claim 13, in the manufacture of a medicament for treatment and/or prophylaxis of lung inflammation disorders, particularly of chronic-obstructive lung disease (COPD), of pulmonary emphysema, of chronic bronchitis, of bronchiectasis, of pulmonary hypertension in COPD (PH-COPD), of acute exacerbation in COPD, of cystic fibrosis (mucoviscidosis, CF), of asthma, and idiopathic pulmonary fibrosis (IPF), of bronchiolitis obliterans syndrome (BOS), of arteriosclerosis, of myocarditis, and of inflammatory skin and eye disorders or inflammatory disorders of the internal organs.